This trial is testing a new drug to see if it can help people with RSV who are at high risk for complications.
1 Primary · 18 Secondary · Reporting Duration: Days 3, 5, 9, and 14
Experimental Treatment
Non-Treatment Group
180 Total Participants · 2 Treatment Groups
Primary Treatment: EDP-938 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: